Literature DB >> 1500751

Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979.

M B Aldous1, J T Grayston, S P Wang, H M Foy.   

Abstract

Incidence rates of Chlamydia pneumoniae infection and information on reinfection and transmission within families were obtained by serologic study of serum samples from prospective family studies conducted 1966-1979. Specimens (n = 3671) from 343 subjects in 68 families were tested for TWAR antibody using the microimmunofluorescence assay. Acute infection was defined as a fourfold rise in antibody titer between consecutive specimens. Sixty-four episodes of infection were identified in 58 persons; 4 had 2 infections and 1 had 3. From late 1975 until early 1979, when 3 serum specimens were collected yearly, rates of infection by age groups 0-4, 5-9, 10-14, 15-19, and greater than or equal to 20 years were 0, 9.2, 6.2, 2.2, and 1.5/100 person-years, respectively. Reinfections, defined as infections in persons with previous antibody, constituted most acute infections among adults. Acute infections more often affected a single family member than multiple members, but 2 or 3 family members were infected during the same period 12 times.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500751     DOI: 10.1093/infdis/166.3.646

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Laboratory diagnosis of Chlamydia pneumoniae infections.

Authors:  R W Peeling
Journal:  Can J Infect Dis       Date:  1995-07

Review 2.  Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Authors:  J Thomas Grayston; Robert J Belland; Gerald I Byrne; Cho Chou Kuo; Julius Schachter; Walter E Stamm; Guangming Zhong
Journal:  Pathog Dis       Date:  2014-12-04       Impact factor: 3.166

3.  Chlamydia pneumoniae.

Authors:  T J Marrie
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

4.  Transport and storage conditions for cultural recovery of Chlamydia pneumoniae.

Authors:  M Maass; K Dalhoff
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

5.  Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.

Authors:  K Nakata; Y Okazaki; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

6.  Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Authors:  Corinna Hermann; Kathrin Graf; Annemarie Groh; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

7.  Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae.

Authors:  K Persson; J Boman
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

8.  Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.

Authors:  Joachim Schessl; Birgit Luther; Janbernd Kirschner; Gottfried Mauff; Rudolf Korinthenberg
Journal:  Eur J Pediatr       Date:  2006-05-12       Impact factor: 3.183

9.  A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis.

Authors:  Z P Yang; C C Kuo; J T Grayston
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections.

Authors:  Corinna Hermann; Katja Gueinzius; Albrecht Oehme; Sonja Von Aulock; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.